Full text is available at the source.
Abstract
Evidence indicates that incretin-based agents and PPARγ agonists may synergistically activate Nrf2 and inhibit NF-kB signaling.
- Incretin-based therapies and PPARγ agonists are associated with improved oxidative status.
- These agents may lead to increased levels of beneficial adipokines like adiponectin and omentin.
- There is a potential reduction in levels of harmful adipokines such as resistin, leptin, and TNF-α.
- Combined activation of incretin and PPARγ pathways could offer antioxidant and anti-inflammatory benefits.
- This modulation of the adipokine-Nrf2 axis may contribute to reduced cardiovascular risk in diabetes.
Simplified